CCL2, a classical chemokine, was initially thought to be involved in immune cell infiltration and inflammatory responses. Recently, it has been found to be closely associated with the pathogenesis of several malignancies. CCL2 and its receptor CCR2 form the CCL2-CCR2 signaling axis, which plays a role in pathological angiogenesis, cell growth, migratory movement and immunosuppression of gliomas, promoting their proliferation, invasion and recurrence. In addition, the expression level of CCL2 is highly correlated with the prognosis of glioma patients and is expected to be a potential biomarker to determine the prognosis of glioma in the future.The purpose of this article is to summarize the relevant studies in recent years and review the progress of research on the molecular mechanisms related to the involvement of CCL2 in glioma cell growth, invasion, angiogenesis, immunosuppression, cell recruitment and the clinical significance of CCL2 in glioma.